What's New?
The HALO™ Breast Pap Test gives doctors and patients a new method to monitor breast cancer risk, quickly and easily. The fact is, all women are at risk for developing breast cancer. In the US we spend $3 billion annually on breast cancer screening, yet more than 70% of lumps are discovered during self-exams. Unfortunately, by the time a woman can actually feel the lump, the disease is no longer in its earliest, most treatable stage.
Routine assessment with HALO will enable breast health monitoring and the ability to react to cellular changes early. The HALO™ Breast Pap Test has been FDA approved for the collection of nipple aspirate fluid for cytological evaluation. The test takes five minutes and is non-invasive. Fluid is collected by the Halo device which works very much like a breast pump used when breastfeeding.. If fluid is found, it can be used in the determination and/or differentiation of normal versus pre-malignant versus malignant cells. Regular assessment and tracking of cellular changes in the milk ducts, where most breast cancer begins, enables clinicians and patients to take control of breast health. If no fluid is found- this is a normal result and subsequent screening is recommended yearly
Like the cervical Pap test, HALO is not a diagnostic test and it cannot be used to exclude breast cancer. Patients should continue to undergo other clinical breast screening procedures (mammography, clinical breast examination, self breast examination) as determined by and with their physicians.
The Halo Breast Pap Test is available at your convenience at Long Island Breast Care. To schedule this exam, please call 516-487-8888 x110.
Call: 516-487-8888
Long Island Breast Care
Make Us A Part of Your Life
January 8, 2011 ONCOTYPE DX: Information That Can Help Define Treatment Options and
Make Treatment Decisions for Breast Cancer PatientsThe Oncotype DX breast cancer assay, is a test that examines a breast cancer patient´s tumor tissue at a molecular level, and gives information about her individual disease. This information can help individualize breast cancer treatment planning and identify options. The Oncotype DX breast cancer test is the only multigene expression test commercially available that has clinical evidence validating its ability to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. The Oncotype DX gene expression assay is intended to be used by women with early-stage (stage I or II), node-negative, estrogen receptor-positive (ER+) invasive breast cancer who will be treated with hormone therapy.
The Oncotype DX breast cancer multigene expression assay has been extensively evaluated in 14 clinical studies involving more than 4,000 breast cancer patients worldwide, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology.
Both the American Society of Clinical Oncology and the National Comprehensive Cancer Network recommend the use of Oncotype DX for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive. For complete information on Oncotype DX for Patients & Caregivers, Healthcare Providers, and Managed Care Organizations, visit OncotypeDX.com.
For additional information for Patients & Caregivers and detail about breast cancer treatment options, visit MyTreatmentDecision.com.
"A Division of ProHEALTH Care Associates, L.L.P."
